Skip to content
Menu

Medtronic plc MDT

Full chart Compare
Set alert

Price alert · MDT

All alert types
99.94 USD -0.67 (-0.67%)

Regular-session close

99.68 -0.26 -0.26%

After hours · Nov 20, 6:08 PM ET

99.60 Day range 102.61
73.75 52-week range 105.35
YTD
+4.04%
1 year
+0.59%

5D -4.40 (-4.21%)

100102104MonTueWedThuFri100.02
Market cap
127.84B
Revenue (ttm)
37.54B
Profit margin
13.93%
EPS (ttm)
4.07
Shares out
1.28B
P/E ratio
24.56
Forward P/E
15.61
Dividend
2.88 (2.86%)
Ex-dividend date
Sep 25, 2026
YTD return
+4.04%
1-year return
+0.59%
Volume
9.03M
Avg volume
16.53M
Open
101.42
Previous close
100.61
Day's range
99.60 – 102.61
52-week range
73.75 – 105.35
Beta
0.57
Analysts
Buy
Price target
106.96 (+7.0%)
Earnings date
Nov 24, 2026
50-day average
94.45

Key statistics

200-day average
88.24
Enterprise value
148.65B
PEG ratio
1.81
Price / sales
3.41
Price / book
2.55
Payout ratio
70.02%
Revenue growth
13.70%
Free cash flow
5.40B
Total cash
8.82B
Total debt
28.15B
Return on equity
10.65%
Short % of float
1.80%

Fundamental scorecard

19 of 25 checks passed on MDT’s reported financials

ValueGrowthProfitabilityHealthDividend

19of 25 checks passed

  • Value 2 of 5
  • Growth 4 of 5
  • Profitability 4 of 5
  • Financial health 4 of 5
  • Dividend 5 of 5

Statements to Jul 31, 2026.

Financials — quick view

All financials
MDT Revenue — quarterly 9.76B
MDT Net income — quarterly 1.47B
MDT EPS — quarterly 1.15

Earnings

MDT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 24, 2026Oct 31, 20261.33———
Sep 1, 2026Jul 31, 20261.391.45+0.06+4.32%
Jun 3, 2026Apr 24, 20261.541.55+0.01+0.65%
Feb 17, 2026Jan 23, 20261.341.36+0.02+1.49%
Nov 18, 2025Oct 24, 20251.311.36+0.05+3.82%
Aug 19, 2025Jul 25, 20251.231.26+0.03+2.44%

Upgrades / downgrades

MDT analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026BTIGmainBuyBuy
Oct 7, 2026Barclaysinit—Equal-Weight
Sep 30, 2026TD CowenreitBuyBuy
Sep 3, 2026UBSmainBuyBuy
Sep 2, 2026Truist SecuritiesreitHoldHold
Sep 2, 2026Wells FargomainOverweightOverweight

About Medtronic plc

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Sector
Healthcare
Industry
Medical Devices
Country
Ireland

News

Your note

Sign in to keep a note on MDT — it syncs with the Stock Master app.

Insider holders

MDT insider holders
InsiderRelationLatest transactionDateShares held
ARNOLD CRAIGDirectorStock Award(Grant)Apr 26, 202642,185
CORONA GARY LOUISChief Financial OfficerStock Award(Grant)Jan 20, 202544,255
HOGAN RANDALL J IIIDirectorStock Award(Grant)Apr 26, 202648,998
KIIL HARRY SKIPOfficerSaleSep 15, 202642,186
MARINARO MICHAELPresidentStock Award(Grant)Nov 1, 2026113,353
MARTHA GEOFFREY SChief Executive OfficerStock Award(Grant)Aug 2, 2026327,866

Institution ownership

MDT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.29%118,770,88511.88BSep 29, 2026
Vanguard Capital Management LLC6.55%83,752,6628.38BSep 29, 2026
State Street Corporation5.16%65,987,3546.60BSep 29, 2026
Vanguard Portfolio Management LLC2.68%34,302,9433.43BSep 29, 2026
Geode Capital Management, LLC2.41%30,879,7773.09BSep 29, 2026
JPMORGAN CHASE & CO1.70%21,712,8562.17BSep 29, 2026

Fund ownership

MDT fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.19%40,757,4224.08BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.60%33,271,4573.33BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%17,056,2981.71BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%16,635,4181.66BSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%15,820,5821.58BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Value Index Fund0.96%12,221,6431.22BJun 29, 2026